Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 Recombinant Pseudomonas Vaccine Intensive Care Patients

NCT01563263 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT01563263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01563263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 Recombinant Pseudomonas Vaccine Intensive Care Patients
Lead sponsor
Valneva Austria GmbH
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2012
Completion date
December 31, 2015
Enrollment
803 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

pseudomonas aeruginosa infection